Monopar Therapeutics (NASDAQ:MNPR) Stock: Insider Kim Tsuchimoto Sells 2,891 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 2,891 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $71.26, for a total value of $206,012.66. Following the completion of the sale, the director owned 1,199 shares of the company’s stock, valued at $85,440.74. This trade represents a 70.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Up 4.2%

NASDAQ MNPR traded up $2.92 on Wednesday, reaching $72.81. 189,611 shares of the stock traded hands, compared to its average volume of 143,006. Monopar Therapeutics Inc. has a 12 month low of $50.07 and a 12 month high of $124.82. The company has a market cap of $488.56 million, a price-to-earnings ratio of -33.55 and a beta of 1.62. The firm’s fifty day simple moving average is $88.66 and its 200 day simple moving average is $77.40.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. As a group, equities research analysts forecast that Monopar Therapeutics Inc. will post -2.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MNPR has been the subject of several research reports. Morgan Stanley restated an “overweight” rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research report on Monday, August 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. HC Wainwright increased their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $109.00 to $119.00 in a report on Thursday, August 13th. Finally, Zacks Research lowered shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $122.00.

Institutional Trading of Monopar Therapeutics

Hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new stake in shares of Monopar Therapeutics in the second quarter worth $7,124,000. Bank of America Corp DE grew its holdings in shares of Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after buying an additional 53,336 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Monopar Therapeutics during the first quarter valued at $250,000. Finally, Siren L.L.C. raised its position in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after buying an additional 57,820 shares during the period. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.